Key Points
- CEO Berndt Modig sold 2,292 Pharvaris shares on May 18 at an average price of $29.22, totaling about $66,972. After the sale, he still held 137,500 shares valued at roughly $4.02 million.
- This was part of a recent pattern of insider selling, including another 2,292-share sale on April 16 and a much larger 23,333-share sale on April 9.
- Pharvaris shares were up 1.7% and the company recently reported a narrower-than-expected quarterly loss of $0.70 per share, while analysts currently maintain a consensus Moderate Buy rating.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $29.22, for a total transaction of $66,972.24. Following the completion of the sale, the chief executive officer directly owned 137,500 shares of the company's stock, valued at $4,017,750. The trade was a 1.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Berndt Modig also recently made the following trade(s):
- On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total transaction of $65,551.20.
- On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42.
Pharvaris Trading Up 1.7%
Shares of PHVS stock opened at $29.45 on Thursday. The company has a market capitalization of $1.93 billion, a PE ratio of -9.26 and a beta of -2.34. The firm has a fifty day simple moving average of $28.32 and a 200-day simple moving average of $26.73. Pharvaris N.V. has a twelve month low of $15.46 and a twelve month high of $33.33.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts predict that Pharvaris N.V. will post -3.25 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in Pharvaris during the 4th quarter valued at $35,000. Barclays PLC bought a new position in Pharvaris during the 4th quarter valued at $77,000. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the 3rd quarter valued at $75,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after acquiring an additional 783 shares during the last quarter.
Analyst Ratings Changes
PHVS has been the subject of several analyst reports. Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday, April 6th. Wall Street Zen upgraded shares of Pharvaris from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 16th. Citigroup restated a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Wedbush upped their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.18.
Get Our Latest Analysis on Pharvaris
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
